GSK to Shutter Emergen-C Powdered Drink Mix PlantGSK to Shutter Emergen-C Powdered Drink Mix Plant

Pharmaceutical firm GlaxoSmithKline (GSK) is moving forward on plans to close its manufacturing plant in Carlisle, PA by mid-2021, several regional news organizations reported this week. Production of Emergen-C powdered Vitamin C supplement drink mix products at the site will be shifted to a facility in Puerto Rico. 

“After careful review, GSK has decided to close the Carlisle, PA site to consolidate volumes and generate efficiencies by moving the site’s production to our Guayama, Puerto Rico facility,” the company said in a statement issued to the Shippensburg News-Chronicle. “Based on this decision, which impacts approximately 260 employees, production will be phased out of Carlisle by mid-2021, with a full exit by the end of 2021.”

The company said the relocation of production will not impact the availability of Emergen-C products in the U.S. or internationally. 

Click here for information about the upcoming International Powder & Bulk Solids Conference/Exhibition

Production of the drink mix started at the Carlisle plant in 2011 by the brand’s original owner, Alacer Corp., according to coverage by news website PennLive.com. Alacer was bought by Pfizer in 2012, and then Pfizer and GSK merged their consumer healthcare businesses under a joint venture in 2018. PennLive said a 10-year lease on the site is expiring at about the same time the plant is slated to close. 

The global market for Vitamin C supplements is expected to grow at a CAGR of 2.48% between 2019 and 2024, reaching a value of $10.17 billion by the end of the period, business insights firm Market Research Future said in a report published this month. 

For more news headlines, articles, and equipment reviews, visit our Equipment Zones

More Powder & Bulk Solids articles:

Massive Blaze Sparked at ExxonMobil Facility

Conveying Equipment Orders Soar 235%

Kice Industries Names New VP of Sales